Signal Pharmaceuticals, Inc.

N.v. Organon

Pharmacopeia Inc.

Merck Sharp + Dohme B.v.

Pharmacopeia Drug Discovery, Inc.

Patrick Anthony Jokiel

Jeffrey John Letourneau

Koc-Kan Ho

Michael H Ohlmeyer

Anusuya Choudhury

Christopher Mark Riviello

Juan Antonio Gamboa

William Wei-Hwa Leong

Susan Elizabeth Napier

Philip Pye

John J Sapienza

Patrick Papa

Jan Elsner

Deborah Mortensen

Garrick Kenneth Packard

Jennifer Riggs

Jingjing Zhao

Sophie Perrin-Ninkovic

Matthew Michael Kreilein

Roy Leonard Harris, Iii

Mohit Atul Kothare

Graziella I Shevlin

Branden Gingsee Lee

Marie Georges Beauchamps

John Richard Morphy

Irina Neagu

Jui-Hsiang Chan

Paul David Ratcliffe

Roy L Harris, Iii

Michael J Ohlmeyer

Fiona Jeremiah

Jurgen Schulz

Duncan Robert McArthur

Koc-Kan Hoc

Jeffrey Letourneau

Duncan Robert Mcarthur

Graziella Shevlin

Roy L Harris

Garrick Packard

John Sapienza

Jeremiah Fiona

Schulz Jurgen

Jui Hsiang Chan

Provided herein are methods to prepare Heteroaryl Compounds having the following structure: 

Methods of synthesis and purification of heteroaryl compounds

Substituted pyridines, pyrimidines, pyrazines, pyridinones, pyrimidinones, pyrazinones and phenylacetamides useful in treating depression, stress and other disorders are disclosed. The compounds are of the formualae: Other embodiments are also disclosed.

Azinone and diazinone V3 inhibitors for depression and stress disorders

Disclosed herein are 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivative of formula I, or pharmaceutically acceptable salts or solvates thereof wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions comprising 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivatives according to the present invention and their use in therapy.

[object Object]

Disclosed herein are quinazolinone or isoquinolinone derivatives of formula I, or pharmaceutically acceptable salts or solvates thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions comprising quinazolinone or isoquinolinone according to the present invention and its use in therapy.

Quinazolinone and isoquinolinone acetamide derivatives

The present invention relates to 2-(4-oxo4H-quinazolin-3-yl) acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression. 

2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists

Growing community of inventors

Princeton, NJ, United States of America

Patrick Anthony Jokiel